Allurion Launching Clinical Study on Combining GLP-1 Therapy with Allurion Program to Optimize Muscle Mass

January 24, 2025

DENVER, Colo., Jan 24, 2025 (247marketnews.com)-Allurion Technologies (NYSE: ALUR) plans to initiate a clinical study exploring the combination of its Allurion Program with GLP-1 agonists to optimize muscle mass and improve overall body composition.

Previous research has shown that GLP-1 therapy often leads to a reduction in lean muscle mass, with about 40% of weight lost coming from lean tissue. In contrast, patients using the Allurion Balloon, paired with the Allurion Virtual Care Suite, have demonstrated strong outcomes by losing weight while maintaining, or even increasing, muscle mass. In a study involving 571 patients, those treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight in just four months. Another study of 167 patients showed a 15.7% reduction in weight with no muscle mass loss.

Dr. Shantanu Gaur, Allurion’s Founder and CEO, said, “Muscle wasting and reductions in lean mass are significant unmet needs in the GLP-1 treatment space. We believe that combining the Allurion Balloon and Virtual Care Suite with GLP-1 therapy could help patients achieve substantial weight loss while improving muscle mass and body composition. If successful, this combination could revolutionize obesity treatment and set a new standard for GLP-1 therapy.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ALUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.